RxDoctor Payments Data

Adriel Malave, MD

Pulmonary Disease · Denver, CONPI 1457535403

Payments from drug & device makers

$6,390in general payments, 2019–2025

Across 35 payments — averaging $182.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$6K
  • Bayer$200
  • Covidien LP$114
  • Merck$105
  • Boehringer Ingelheim$74
  • E.r. Squibb & Sons, L.L.C.$64
  • plus $158 from 7 others

What the payments were for

  • Consulting fees$2003%
  • Speaking & faculty fees$4,29067%
  • Travel & lodging$6049%
  • Food & beverage$1,28820%
  • Education$80%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,390 in reported general payments places this provider in the 70th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$57,434
Medicare patients
263
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan24$302,176
UptraviSelexipag12$280,019
AdempasRiociguat19$267,666
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr127$69,706
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$69,363
Breo ElliptaFluticasone/Vilanterol58$28,685
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$15,136
SymbicortBudesonide/Formoterol Fumarate36$12,370
EliquisApixaban16$9,427
Spiriva RespimatTiotropium Bromide11$7,701
DuleraMometasone/Formoterol11$3,716
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$2,750
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,679
Albuterol Sulfate HfaAlbuterol Sulfate69$1,966
Tadalafil20$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$5,673$582,19536 claims
BayerAdempas$200$267,66619 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$24$167,754265 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$74$22,83739 claims
AstraZenecaSymbicort$23$12,37036 claims
MerckDulera$105$3,71611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →